CRMD
Price
$5.30Alerts
Change
-$0.07 (-1.30%)
Updated
Nov 11 closing price
Capitalization
414.66M
Earnings call today
Intraday BUY SELL Signals
XLO
Price
$8.47Alerts
Change
-$0.06 (-0.70%)
Updated
Nov 11 closing price
Capitalization
57.71M
111 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CRMD vs XLO

CRMD vs XLO Comparison Chart in %
View a ticker or compare two or three
VS
CRMD vs. XLO commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRMD is a Hold and XLO is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for CRMD with price predictions
Nov 11, 2026

CRMD's RSI Indicator is remaining in oversold zone for 8 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +4.59% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRMD advanced for three days, in 230 of 285 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

CRMD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CRMD as a result. In 73 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.

The Moving Average Convergence Divergence Histogram (MACD) for CRMD turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 31 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 77%.

CRMD moved below its 50-day moving average on October 29, 2026 date and that indicates a change from an upward trend to a downward trend.

The 50-day moving average for CRMD moved below the 200-day moving average on November 04, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

The Aroon Indicator for CRMD entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 19 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. CRMD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.900) is normal, around the industry mean (3.498). P/E Ratio (2.163) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (5.636) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1.564) is also within normal values, averaging (440.869).

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 97 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for XLO with price predictions
Nov 11, 2026

XLO's Stochastic Oscillator is remaining in overbought zone for 5 days

The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

XLO moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XLO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

The Aroon Indicator for XLO entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where XLO's RSI Oscillator exited the oversold zone, 27 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.

The Momentum Indicator moved above the 0 level on November 03, 2026. You may want to consider a long position or call options on XLO as a result. In 76 of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.

The Moving Average Convergence Divergence (MACD) for XLO just turned positive on November 03, 2026. Looking at past instances where XLO's MACD turned positive, the stock continued to rise in 40 of 45 cases over the following month. The odds of a continued upward trend are 89%.

Following a +4.65% 3-day Advance, the price is estimated to grow further. Considering data from situations where XLO advanced for three days, in 158 of 208 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

XLO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.799) is normal, around the industry mean (3.498). P/E Ratio (-27.406) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (2.000) is also within normal values, averaging (440.869).

The Tickeron PE Growth Rating for this company is 48 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 69 (best 1 - 100 worst), indicating slightly worse than average price growth. XLO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XLO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
CRMD: Fundamental Ratings
CRMD
OUTLOOK RATING
1..100
15
VALUATION
overvalued / fair valued / undervalued
1..100
87
Overvalued
PROFIT vs RISK RATING
1..100
97
SMR RATING
1..100
19
PRICE GROWTH RATING
1..100
82
P/E GROWTH RATING
1..100
97
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CRMDXLO
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
87%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 1 day ago
78%
MACD
ODDS (%)
Bearish Trend 1 day ago
77%
Bullish Trend 1 day ago
89%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
88%
Advances
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
76%
Declines
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
88%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
85%
Aroon
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
85%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (CRMD: $5.30 vs. XLO: $8.53)
Brand notoriety: CRMD and XLO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRMD: 123% vs. XLO: 6%
Market capitalization -- CRMD: $414.66M vs. XLO: $57.71M
CRMD [@Biotechnology] is valued at $414.66M. XLO’s [@Biotechnology] market capitalization is $57.71M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRMD’s FA Score shows that 1 FA rating(s) are green while XLO’s FA Score has 1 green FA rating(s).

  • CRMD’s FA Score: 1 green, 4 red.
  • XLO’s FA Score: 1 green, 4 red.
According to our system of comparison, XLO is a better buy in the long-term than CRMD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRMD’s TA Score shows that 4 TA indicator(s) are bullish while XLO’s TA Score has 5 bullish TA indicator(s).

  • CRMD’s TA Score: 4 bullish, 6 bearish.
  • XLO’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, XLO is a better buy in the short-term than CRMD.

Price Growth

CRMD (@Biotechnology) experienced а -6.36% price change this week, while XLO (@Biotechnology) price change was -1.73% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.

Reported Earning Dates

CRMD is expected to report earnings on Nov 12, 2026.

XLO is expected to report earnings on Nov 12, 2026.

Industries' Descriptions

@Biotechnology (-0.49% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

CRMD and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRMD has been loosely correlated with IMRX. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if CRMD jumps, then IMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRMD
1D Price
Change %
CRMD100%
-1.30%
IMRX - CRMD
48%
Loosely correlated
-1.56%
ABOS - CRMD
45%
Loosely correlated
N/A
ACRV - CRMD
43%
Loosely correlated
N/A
GYRE - CRMD
36%
Loosely correlated
+0.71%
PMN - CRMD
35%
Loosely correlated
-5.53%
More

XLO and

Correlation & Price change

A.I.dvisor tells us that XLO and BLRX have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that XLO and BLRX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XLO
1D Price
Change %
XLO100%
-0.70%
BLRX - XLO
31%
Poorly correlated
+2.72%
CRMD - XLO
31%
Poorly correlated
-1.30%
AXON - XLO
31%
Poorly correlated
+4.26%
HCWB - XLO
29%
Poorly correlated
-6.75%
ANAB - XLO
28%
Poorly correlated
+0.81%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
KRWX9.051.01
+12.50%
Corgi South Korea 2x Daily ETF (KRWX)
SRV36.341.10
+3.12%
NXG Cushing Midstream Energy Fund
URAA14.130.35
+2.54%
DIREXION DAILY URANIUM INDUSTRY BULL 2X SHARES
CORB28.48-0.03
-0.11%
AB Core Bond ETF (CORB)
DMA6.97-0.01
-0.14%
Destra Multi-Alternative Fund